PRASAD SUYASH 4
4 · Taysha Gene Therapies, Inc. · Filed Sep 30, 2020
Insider Transaction Report
Form 4
PRASAD SUYASH
CMO and Head of R&D
Transactions
- Conversion
Common Stock
2020-09-28+3,844→ 672,589 total - Conversion
Series B Preferred Stock
2020-09-28−3,529→ 0 total→ Common Stock (3,844 underlying)
Footnotes (1)
- [F1]Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date.